UroGen Pharma (URGN) Total Non-Current Liabilities (2019 - 2026)

UroGen Pharma (URGN) has reported Total Non-Current Liabilities for 8 consecutive years, with $374.0 million the latest figure, recorded in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 28.85% year-over-year to $374.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $374.0 million (up 28.85% YoY) and the FY2025 annual result came in at $302.0 million, up 3.89% from the prior year.
• Total Non-Current Liabilities advanced to $374.0 million in Q1 2026 per URGN's latest filing, from $302.0 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for URGN reached as high as $374.0 million in Q1 2026 and fell as low as $179.9 million in Q1 2022.
• A 5-year average of $253.9 million and a median of $240.3 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 888.39% — and 2025, when it climbed 3.89%.
• Year by year, Total Non-Current Liabilities stood at $222.0 million in 2022, then grew by 8.27% to $240.3 million in 2023, then rose by 20.97% to $290.7 million in 2024, then grew by 3.89% to $302.0 million in 2025, then advanced by 23.84% to $374.0 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $374.0 million, $302.0 million, and $296.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.